BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Tasting America: An Excursion Through Darling Cheap Food Brands - 2Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- 3This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 4Who is behind Al-Majd, the Israeli-linked evacuation group sending Gazans to South Africa?
- 5Picking Childcare Administrations for Your Loved ones
- Grasping Wrongdoings and Crimes: A Correlation
- Newly Identified ‘Lucy’s Hunter’ Was a 15-Foot Crocodile Lurking in Ancient Ethiopia
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- NASA begins the countdown for humanity's first launch to the moon in 53 years
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- China resumes flights to North Korea after a six-year pause
- Upgrading the Healthy benefit of Your Local Vegetables
- 4 Jeep Models: Dominating Execution and Flexibility for Each Experience
